September 12, 2006– /BUSINESS WIRE/ — SAN DIEGO — Bio-Matrix Scientific Group Inc. (OTCBB:BMSN), a biotechnology company focused on stem cell cryogenics and disposable stem cell / tissue transfer instruments, announced today that Clean Rooms West has started the installation process of its modular class 10,000/100 Stem Cell Processing laboratory. Bio-Matrix Scientific is now entering into the final phase of renovation and construction of its 15,000 sq ft Stem Cell Cryogenic Bank.
Clean Rooms West has begun the preparatory work for the installation of the modular clean which has been built to Bio-Matrix’ specifications. The laboratory will house the company’s stem cell processing systems. It is anticipated the actual lab will arrive later this week, with final completion scheduled for the first part of October 2006.
Following an intense, best value search, Bio-Matrix Scientific selected Clean Rooms West as the prime contractor to design, develop, build and install the new class 10,000 processing laboratory.
Brian Pockett, Managing Director and COO, stated, “The construction and completion of this laboratory is a major step towards our ability to accept and process adult stem cells.”
Bio-Matrix’ new 15,000 sq ft state-of-the-art, located in the heart of the San Diego biotechnology will house Bio-Matrix’ secure Cryogenic Stem Cell Bank, 3 Research laboratories, aseptic cellular/tissue class 10,000/100 processing laboratory, hematology, microbiology and flow cytometry laboratories.
About Bio-Matrix Scientific Group Inc.
Bio-Matrix Scientific Group Inc. (www.BMXGonline.com), is a biotech research and development Company that commercializes medical devices and monitoring systems for the growing, worldwide stem cell research market.
The Company aligns itself with strategic partners that offer key technologies in biomedical device development, tissue engineering, cell culturing, genome therapy and drug delivery systems to become a leading source for stem cell research technology and innovation and is building a state-of-the-art facility in San Diego, California, to cater to the growing stem cell research segment of the $75 billion biotechnology and medical device industry.
DISCLAIMER: This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
Contacts
Bio-Matrix Scientific Group Inc.
Investor Relations, 619-398-3517
[email protected]
or
AGORA Investor Relations
[email protected]
http://www.agoracom.com/IR/Bio-Matrix